1. Scrip
  2. >>Leadership

Ranbaxy Family Feud: Transparency And Ethics “Continuously Negated” Says Younger Brother

 
• By Anju Ghangurde

The Singh brothers of Ranbaxy are now engaged in a bitter feud, with the younger sibling Shivinder hauling his brother Malvinder to the National Company Law Tribunal over alleged mismanagement of group firms. It remains to be seen how things play out but Daiichi Sankyo, which is pressing for enforcement of an arbitration award against the brothers, may well claim "we told you so."

Fists
THE SINGH BROTHERS ARE INVOLVED IN A VERY PUBLIC SPAT IN INDIA

Ranbaxy Laboratories Ltd.’s founding family is once again engaged in a very public spat – this time younger scion Shivinder Singh has moved the National Company Law Tribunal (NCLT) accusing his older sibling Malvinder Singh and their close family associate Sunil Godhwani of “oppression and mismanagement” of group firms RHC Holding, Religare and Fortis Healthcare.

Godhwani is a former CEO of Religare, which ironically means ‘bind together’ in Latin, and the executive, was, in the past, described as “guide and mentor” to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.